1Keeling D,Tait C,Makris M.Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders.Haemophilia,2008,14(4):671-684.
2Srivastava A,Brewer AK,Mauser-Bunschoten EP,et al.Guidelines for the management of hemophilia.Haemophilia,2013,19(1):1-47.
4Burnouf T,Burnouf-Radosevich M,Huart JJ,et al.A highly purified factorⅧ:c concentrate prepared from cryoprecipitate by ion-exchange chromatography.Vox Sang,1991,60(1):8-15.
5Weinstein RE.Immunoaffinity purification of factorⅧ.Ann Clin Lab Sci,1989,19(2):84-91.
6Philipp CS,Monoclate-P Study Group.Viral safety of a pasteurized,monoclonal antibody-purified factorⅧconcentrate in previously untreated haemophilia A patients.Haemophilia,2001,7(2):146-153.
7Mark Brooker.Registry of clotting factor concentrates,9th Edition,World Federation of Hemophilia,2012:5-6.
8Octanate—Product information.29 March 2007.
9Mannucci PM.Aids,hepatitis and hemophilia in the 1980's:memories from an insider.J Thromb Haemost,2003,1(10):2065-2069.
10Johnson AJ,Newman J,Howell MB,et al.The preparation and some properties of a clinically useful,high purity antihaemophilic factor(AHF).Bibliotheca Haematologica,1968,29:1109.
